Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $5.93, for a total transaction of $130,460.00. Following the transaction, the director owned 1,166,391 shares in the company, valued at approximately $6,916,698.63. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vir Biotechnology Stock Down 2.5%

Shares of VIR opened at $5.79 on Tuesday. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The company’s fifty day moving average is $5.98 and its two-hundred day moving average is $5.53. The firm has a market cap of $805.50 million, a PE ratio of -1.60 and a beta of 1.39.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. Vir Biotechnology’s revenue was up .8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.56) EPS. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

VIR has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.30.

Institutional Investors Weigh In On Vir Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Vir Biotechnology by 1.4% during the third quarter. JPMorgan Chase & Co. now owns 449,518 shares of the company’s stock valued at $2,567,000 after acquiring an additional 6,143 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Vir Biotechnology during the third quarter worth approximately $38,000. Hudson Bay Capital Management LP grew its holdings in Vir Biotechnology by 31.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 911,882 shares of the company’s stock worth $5,207,000 after acquiring an additional 215,882 shares in the last quarter. Connective Capital Management LLC bought a new stake in Vir Biotechnology in the third quarter valued at about $431,000. Finally, Sender Co & Partners Inc. acquired a new stake in shares of Vir Biotechnology during the 3rd quarter valued at approximately $247,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.